PROGLYCEM SUSPENSION Rx
Generic Name and Formulations:
Diazoxide 50mg/mL; chocolate-mint flavor; contains alcohol 7.25%.
Indications for PROGLYCEM SUSPENSION:
Management of hypoglycemia due to hyperinsulinism associated with: inoperable islet cell adenoma or carcinoma, or extrapancreatic malignancy in adults; leucine sensitivity, islet cell hyperplasia, nesidioblastosis, extrapancreatic malignancy, islet cell adenoma, or adenomatosis in infants and children.
Adults and Children:
Individualize. Infants and newborns: Initially 10mg/kg/day divided into 3 equal doses every 8hrs. Usual range: 8–15mg/kg divided into 2–3 equal doses every 8–12hrs. Adults and children: Initially 3mg/kg/day divided into 3 equal doses every 8hrs. Usual range: 3–8mg/kg divided into 2–3 equal doses every 8–12hrs. Refractory hypoglycemia: may require higher dosages. Discontinue if not effective after 2–3 weeks.
Functional hypoglycemia. Thiazide hypersensitivity.
Compromised cardiac reserve: may precipitate CHF. Hyperuricemia. History of gout. Renal impairment: consider reducing dose; evaluate serum electrolyte levels. Newborns with increased bilirubinemia. Monitor for respiratory distress (esp. in those with risk factors); discontinue if pulmonary hypertension is suspected. Monitor blood glucose, BUN, creatinine clearance, hematocrit, platelets, total and differential leukocyte counts, AST, serum uric acid periodically until stabilized. Labor & delivery. Pregnancy (Cat.C). Nursing mothers: not recommended.
Nondiuretic benzothiadiazine derivative.
Antihypertensives potentiated. Concomitant coumarin: may need to reduce dose of anticoagulant. Concomitant diphenylhydantoin may result in loss of seizure control. Concomitant thiazides, other diuretics may potentiate hyperglycemic and hyperuricemic effects. Inhibits glucagon-stimulated insulin release and causes false-negative insulin response to glucagon.
Sodium and fluid retention, diabetic ketoacidosis, hyperosmolar nonketotic coma, hirsuitism, hyperglycemia, glycosuria, GI upset, tachycardia, palpitations, increased serum uric acid, thrombocytopenia (may require discontinuation), neutropenia, rash, headache, weakness, malaise.
Susp—30mL (w. dropper)
Sign Up for Free e-newsletters
- Study Finds Association Between Folate Intake and Risk of Cutaneous Melanoma
- Carfilzomib Benefits May Outweigh Cardiovascular Risk in Multiple Myeloma
- Bariatric Surgery Reduced Risk of Some Cancers in Obese Patients
- The Caregivers' Cancer Journey
- Genetic Link Between Depression and Breast Cancer Remains Unclear
- Implementing an Ambulatory Adherence Program May Improve Oral Anticancer Medications Compliance
- Exercise Habits Influence Mortality in Adult Survivors of Childhood Cancer
- Managing Dyspnea With Fentanyl in Patients With Cancer at End of Life
- CALM: A Depression Intervention for Cancer Patients at the End of Life
- High BMI Among Premenopausal Women May Improve Risk for Breast Cancer
- Fertility Preservation in Hodgkin's Lymphoma Patients That Undergo Targeted Molecular Therapies: An Important Step Forward From the Chemotherapy Era
- Survey of ACEP Councilors Reveals NP, PA Staffing Models, Practice Patterns Vary
- Breath Analysis May Be an Effective Diagnostic for Pancreatic Cancer
- Genetic Susceptibility to Pancreatic Cancer Linked to 6 Specific Gene Mutations
- Dinner Hour and Sleep Habits Affect Risk of Breast, Prostate Cancers
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|